Pathologist Pediatric In-Patient Genetic Stewardship
Background: Costs for sendout genetic testing on in-patients are billed to the hospital. Turnaround times are several weeks, often extending past the inpatient hospitalization.Materials and Methods: We concurrently reviewed all sendout genetic in-patient test requests over an 18-month period, deferring those that could be obtained as an outpatient, directing the tests to less expensive laboratories with complementary testing profiles, and identifying no-charge sponsored tests.Results: Of 121 test requests, 25 were deferred, alternative less expensive laboratories were identified for 8, 16 requests were directed to sponsored tests, for a 42.3% cost saving. Of the 96 tests sent, 18 (18.8%) identified an explanatory genetic abnormality.Conclusions: Approximately 40% of the sendout genetic testing costs were reduced with prior test review. Deferment, alternative laboratories, and sponsored tests contributed to cost savings. Efficiency of diagnostic inpatient genetic testing was approximately 20%.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Fetal and pediatric pathology - 42(2023), 6 vom: 03. Dez., Seite 914-921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Craver, Randall [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genetic testing |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15513815.2023.2263790 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362809143 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362809143 | ||
| 003 | DE-627 | ||
| 005 | 20231226092020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15513815.2023.2263790 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362809143 | ||
| 035 | |a (NLM)37787107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Craver, Randall |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pathologist Pediatric In-Patient Genetic Stewardship |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Costs for sendout genetic testing on in-patients are billed to the hospital. Turnaround times are several weeks, often extending past the inpatient hospitalization.Materials and Methods: We concurrently reviewed all sendout genetic in-patient test requests over an 18-month period, deferring those that could be obtained as an outpatient, directing the tests to less expensive laboratories with complementary testing profiles, and identifying no-charge sponsored tests.Results: Of 121 test requests, 25 were deferred, alternative less expensive laboratories were identified for 8, 16 requests were directed to sponsored tests, for a 42.3% cost saving. Of the 96 tests sent, 18 (18.8%) identified an explanatory genetic abnormality.Conclusions: Approximately 40% of the sendout genetic testing costs were reduced with prior test review. Deferment, alternative laboratories, and sponsored tests contributed to cost savings. Efficiency of diagnostic inpatient genetic testing was approximately 20% | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Stewardship | |
| 650 | 4 | |a genetic testing | |
| 650 | 4 | |a in-patient | |
| 650 | 4 | |a pediatric | |
| 773 | 0 | 8 | |i Enthalten in |t Fetal and pediatric pathology |d 2004 |g 42(2023), 6 vom: 03. Dez., Seite 914-921 |w (DE-627)NLM150461623 |x 1551-3823 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:6 |g day:03 |g month:12 |g pages:914-921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15513815.2023.2263790 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 6 |b 03 |c 12 |h 914-921 | ||